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Objectives. The study was designed to evaluate associations between symmetric dimethylarginine (SDMA), inflammation, and
superoxide anion (O
2
∙−) with endothelial function and to determine their potential for screening of endothelial dysfunction in
patients with chronic kidney disease (CKD) and renal transplant (RT) recipients. Materials and Methods. We included 64 CKD
and 52 RT patients. Patients were stratified according to brachial artery flow-mediated dilation (FMD). Results. Logistic regression
analysis showed that high SDMA and high sensitive C-reactive protein (hs-CRP) were associated with impaired FMD in CKD
and RT patients, after adjustment for glomerular filtration rate. The ability of inflammation, SDMA, and O
2
∙− to detect impaired
FMD was investigated by receiving operative characteristic analysis. Hs-CRP (area under the curves (AUC) = 0.754, 𝑃 < 0.001),
IL-6 (AUC = 0.699, 𝑃 = 0.002), and SDMA (AUC = 0.689, 𝑃 = 0.007) had the highest ability to detect impaired FMD. SDMA in
combination with inflammatory parameters and/or O
2
∙− had better screening performance than SDMA alone. Conclusions. Our
results indicate a strong predictable association between hs-CRP, SDMA, and endothelial dysfunction in CKD patients and RT
recipients. The individual marker that showed the strongest discriminative ability for endothelial dysfunction is hs-CRP, but its
usefulness as a discriminatory marker for efficient diagnosis of endothelial dysfunction should be examined in prospective studies.
1. Introduction
Patients with chronic kidney disease (CKD) are at high
risk of developing cardiovascular disease. In addition, renal
transplant (RT) recipients are 10 times more likely to suffer
from fatal cardiac events compared with the general popu-
lation [1]. Many risk factors, traditional and nontraditional,
are involved in the pathogenesis of atherosclerosis in these
patients.
Endothelial dysfunction, oxidative stress, and inflamma-
tion are recognised as new risk factors in CKD patients.
Nevertheless, interplay between these factors remains largely
unexplored.
Impairment of endothelium-dependent vasodilatation
has largely been attributed to reduced availability or biolog-
ical activity of nitric oxide (NO). NO is synthesized from L-
arginine in a reaction catalysed by NO synthase (NOS).
Methionine is metabolised to homocysteine by a de-
methylation pathway. The final result of this pathway is the
formation of asymmetric dimethyl-L-arginine (ADMA), an
NOS inhibitor. Increased ADMA may limit intracellular L-
arginine availability for NO synthesis or inhibit NOS. In
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addition, homocysteine mediates superoxide anion (O
2
∙−)
production. O
2
∙− reacts with NO and forms highly reactive
peroxynitrite capable of causing tissue damage. Furthermore,
O
2
∙− increases ADMA by affecting the activities of protein
arginine N-methyltransferases that synthesize ADMA and
dimethylaminohydrolase which metabolises ADMA. Sym-
metric dimethylarginine (SDMA) is an inactive stereoiso-
mer produced alongside ADMA, and it has recently been
described as a risk factor for cardiovascular events. SDMA
is probably important as a competitive inhibitor of arginine
transport across cell membranes [2, 3]. There is growing evi-
dence that increased plasma ADMA leads to cardiovascular
effects in CKD patients [4]. Furthermore, elevated plasma
ADMA is associated with increasedmorbidity, mortality, and
the deterioration of graft function in RT recipients [5].
The aetiology of endothelial dysfunction is complicated.
It is explained by alter vasoconstrictive/vasodilatatory func-
tion, by triggering inflammatory processes (through NO
and adhesion molecules such as ICAM-1, VCAM-1, and E-
selectin) and by affecting haemostasis (through release of
tissue factor, von Willebrand factor, thromboxane A2, and
fibrinogen) [6]. It is therefore unlikely that a single biomarker
will provide accurate information for endothelial dysfunc-
tion occurrence. Accordingly, simultaneous measurement of
several biomarkers and formulation of models that have
incremental value in endothelial dysfunction screening in
comparison to single biomarker analysis would be useful. For
this reason, numerous researchers are focussed on finding
new markers with high diagnostic accuracy that would
provide a powerful clinical tool for endothelial dysfunction
screening.We have chosen to centre our study on biomarkers
characteristic of nontraditional risk factors: SDMA as an
endothelial marker, O
2
∙− as a marker of oxidative stress,
and inflammatory markers such as high sensitive C-reactive
protein (hs-CRP), interleukin-6 (IL-6), and serum amyloid A
(SAA).
The aim of our study was to determine associations
between SDMA, inflammation, and O
2
∙− with endothelial
function and to evaluate their potential for screening of
endothelial dysfunction in patients with CKD and RT recip-
ients.
2. Material and Methods
This study included 64 stage 2–5 CKD patients not requiring
dialysis and 52 RT recipients at least 6 months after trans-
plantation. All subjects were examined at the Nephrology
Clinic, Clinical Centre of Serbia, and provided information
regarding medication and medical history. Diabetics and
patients with acute inflammatory disease were excluded.
Forty patients received a kidney from a related living donor
and twelve from a cadaver. These patients had previous
transplantation duration of 9.56 ± 5.27 years. Any history of
hypertension, ischemic vascular disease including myocar-
dial infarction, angina pectoris, and cerebral stroke, heart
failure, and smoking were obtained by interview. All patients
with recentmyocardial infarction and thosewith heart failure
were excluded. The immunosuppressive protocol in renal
RT patients consisted of calcineurin inhibitors (cyclosporine
or tacrolimus), mycophenolate acids, or azathioprine and
prednisolone. CKD patients with some type of glomeru-
lonephritis as the origin disease received corticosteroids
or other immunosuppressive therapy according to standard
protocols.
The diameter of the brachial artery was measured for
assessment of endothelial function, and blood was drawn
for biochemical measurements. Patient data included demo-
graphic (sex and age), clinical (duration of renal disease), and
biochemical variables. Clinical and immunological obser-
vations as well as laboratory parameters and endothelial
function were all performed on the same day.
All patients gave informed consent prior to their enrol-
ment in the study, which was planned according to the
ethical guidelines following the Declaration of Helsinki. The
institutional review committee approved our study protocol
thereby following local biomedical research regulations.
2.1. Endothelial Function. This was performed according to
the method originally described by Celermajer et al. [7].
Measurements were performed between 1:00 p.m. and 3:00
p.m. All subjects were instructed not to eat for at least 4
hours before the procedure or consume alcohol, or caffeine-
containing drinks for at least 24 hours prior to the procedure.
Patients lied supine in a quiet temperature-controlled room
for 10 minutes before the examination. The diameter of the
brachial artery was measured from 2D ultrasound images
using a commercially available system (Agilent Image Point
HX) and images were recorded on VHS tape. A baseline
image was obtained at rest 2 to 15 cm above the antecubital
fossa incident with the R-wave on the electrocardiogram.
To create a flow stimulus in the brachial artery, a blood
pressure cuffwas placed on the forearm and inflated to at least
50mmHg above systolic pressure to occlude arterial inflow
for 5 minutes. A second measurement was performed after
60 to 80 seconds after cuff release to endothelial-dependant
flow-mediated vasodilatation of the brachial artery (FMD).
For each measurement, a minimum of three cardiac cycles
was averaged. FMD was calculated as the percentage change
in diameter compared with baseline resting diameter.
2.2. Biochemical Measurements. Blood sampling was per-
formed after 12 hours of fasting overnight in order tomeasure
the following parameters: serum SDMA, amino-terminal
probrain natriuretic peptide (NT-proBNP), creatinine, urea,
uric acid, albumin, total cholesterol, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL) choles-
terol, triglycerides, hs-CRP, IL-6, SAA and plasma fibrinogen,
and O
2
∙−.
The serum samples for determination of SDMA, NT-
proBNP, and IL-6 were stored at −80∘C in aliquots until anal-
ysis. Other parameters were analysed on the day of collection.
Citrated plasma was stored at −70∘C before measurement
of fibrinogen. For the measurement of O
2
∙−, plasma from
heparinised blood samples was used immediately.
Measurement of serum SDMA was determined using
an ELISA (DLD Diagnostica GMBH, Hamburg, Germany).
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NT-proBNP was determined with an ELFA (bioMerieux,
Vidas, Lyon, France). Creatinine, urea, uric acid, albumin,
and lipids were analysed employing routine methods (Olym-
pus System Reagents using an Olympus analyzer AU 2700,
Hamburg, Germany). SAA and hs-CRP were measured
using immunonephelometric assays (Dade-Behring, BN II,
Marburg, Germany). Serum IL-6 level was measured with
a highly sensitive colorimetric sandwich ELISA kit (Human
IL-6 Quantikine HS ELISA kit; R&D Systems, GmbH, Ger-
many). The rate of nitroblue tetrazolium reduction was used
tomeasure the rate of O
2
∙− generation, as described byAuclar
andVoisin [8] (the intraassayCVwas 5.6%, and the interassay
CV was 9.5%). The SDMA reference range is 0.3–0.7𝜇mol/L.
Assessment of renal function was performed via esti-
mated glomerular filtration rate (GFR) using the modified
diet in renal disease equation [9]. Arterial hypertension was
diagnosed when the systolic blood pressure was ≥140mmHg
and/or diastolic pressure was ≥90mmHg, or if antihyper-
tensive treatment was prescribed. Body mass index (BMI)
was calculated according to the following formula: weight
(kg)/height2 (m2).
2.3. Statistical Analyses. Differences in continuous variables
between the groups were analysed by Student’s t-test for
normally distributed variables. Variables with non-Gaussian
distribution were log-transformed to achieve normality.
Adjusted mean levels of SDMA were estimated by analysis of
covariance. Group differences for categorical variables were
examined by the Chi-square test. The CKD and RT patients
were first stratified into tertiles according to inflammatory
parameters, SDMA, and O
2
∙− concentrations. CKD patients
with hs-CRP (hs-CRP ≥ 0.89mg/L), IL-6 (IL ≥ 3.5 pg/mL),
SAA (SAA ≥ 2.5mg/L), SDMA (SDMA ≥ 1.79 𝜇mol/L), and
O
2
∙− (O
2
∙−
≥ 57.5 𝜇mol/min L) in the upper tertile were
defined as having high hs-CRP, IL-6, SAA, SDMA, and O
2
∙−.
Similarly, RT patients with hs-CRP (hs-CRP≥ 2.02mg/L), IL-
6 (IL ≥ 6.1 pg/mL), SAA (SAA ≥ 11.6mg/L), SDMA (SDMA
≥ 1.30 𝜇mol/L), and O
2
∙− (O
2
∙−
≥ 50.1 𝜇mol/min L) in the
upper tertile were defined as having high hs-CRP, IL-6,
SAA, SDMA, and O
2
∙−. The low risk values for examined
parameters (lower than the upper tertile) were coded 0,
while the high risk values (higher than the upper tertile)
were coded 1. Odds ratios (ORs) were calculated using
binary logistic regression analysis to determine whether high
levels of inflammatory parameters, SDMA, and O
2
∙− had
any potential for the prediction of impaired FMD. Factors
that were significant in univariate analysis were adjusted
for GFR concentrations in multivariate logistic regression
analysis to determine the adjusted OR. Accuracy of the
examined parameters was assessed using receiving opera-
tive characteristic (ROC) curve analysis. Parameters with
significant accuracy were combined with other parameters,
curves for these models were plotted and the area under
ROC curves (AUC) was presented as C statistics from the
analysis. For internal validation of the statistically significant
models, we used the percentile bootstrap method, with 1000
resampling simulations, with the aid of the “boot” package of
R.
Data are shown as mean ± standard deviation for nor-
mally distributed continuous variables and as relative or abso-
lute frequencies for categorical variables. Log-transformed
variables were expressed as geometrical mean and 95% confi-
dence interval (CI) formean.All calculationswere performed
using MS Excel, EduStat 2.01 (2005, Alpha Omnia, Belgrade,
Serbia), MedCalc for Windows version 9.6.3. (Mariakerke,
Belgium), and R version 2.15.3. The minimal statistical sig-
nificance was set at 𝑃 < 0.05.
3. Results
To evaluate the effect of endothelial function on the examined
parameters, we stratified CKD and RT patients into FMD
groups. Because of the lack of reference ranges for FMD, we
defined the cutoff values for impaired and nonimpaired FMD
groups [10].The patients had apparently impaired endothelial
function (the first tertile of the FMD values) if the percentage
change in diameter compared with baseline resting diameter
of the brachial artery was lower than 3.8% in CKD and
2.19% in RT patients. However, if the patients had a higher
percentage for FMD (the second and third tertiles of the FMD
values), they were considered as individuals with apparently
nonimpaired endothelial function.
There were no differences in age and gender between
the FMD groups in CKD and RT patients. In CKD patients
inflammatory parameters (hs-CRP, IL-6, and SAA) were
significantly higher in those with impaired FMD, whereas
HDL cholesterol and uric acid were higher in those with non-
impaired FMD (Table 1). Moreover, SDMA was significantly
higher in CKD patients with impaired FMD. RT patients
with impaired FMD had higher LDL cholesterol and lower
albumin.
To explore whether the association between inflamma-
tory parameters, SDMA, lipoproteins, uric acid and albu-
min with endothelial dysfunction was confounded by other
factors, their concentrations in patients with and without
impaired FMD belonging to both study groups (CKD and
RT groups) were compared after adjusting for GFR. After
adjusting for GFR, inflammatory parameters in the CKD
patients with impaired FMD were significantly higher than
the corresponding values in the CKD patients with nonim-
paired FMD (𝐹 = 16.065, 𝑃 < 0.001 for hs-CRP, 𝐹 =
5.624, 𝑃 = 0.026 for IL-6, and 𝐹 = 8.201, 𝑃 = 0.008
for SAA). However, after adjusting for GFR, SDMA and uric
acid were not significantly increased and HDL-cholesterol
was not significantly decreased in the patients diagnosedwith
impaired FMD (𝐹 = 1.33, 𝑃 = 0.262 for SDMA, 𝐹 = 3.58,
𝑃 = 0.069 for uric acid, and 𝐹 = 1.198, 𝑃 = 0.283 for HDL-
cholesterol).
Accordingly, in the RT group, therewas a significant effect
of impaired FMD on LDL-cholesterol after controlling for
the GFR (𝐹 = 4.817, 𝑃 = 0.039). In contrast, adjusted
albumin was not significantly different between RT patients
with impaired and nonimpaired FMD (𝐹 = 1.775, 𝑃 =
0.197).
We used binary logistic regression to determine whether
high hs-CRP, IL-6, SAA, SDMA, and O
2
∙− had any potential
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Table 1: Demographic data, lipid status parameters, inflammatorymarkers and SDMA concentrations in CKD and RT patients with impaired
and nonimpaired FMD.
CKD patients FMD RT patients FMD
Non-impaired
(𝑛 = 44)
Impaired
(𝑛 = 20)
P Non-impaired
(𝑛 = 36)
Impaired
(𝑛 = 16)
P
Age, years 38.4 ± 12.7 44.2 ± 12.0 0.238 39.5 ± 8.8 39.0 ± 8.6 0.894
Male, % 45.5 40.0 0.773 61.1 62.5 0.946
BMI, kg/m2 23.63 ± 3.40 23.09 ± 10.44 0.875 25.48 ± 4.30 25.18 ± 3.11 0.856
CKD duration, months∗ 20.27(10.59–38.80)
88.80
(25.85–151.74) 0.076
140.44
(103.08–177.81)
145.63
(92.79–198.45) 0.811
Creatinine, 𝜇mol/L∗ 233.94(189.45–288.88 )
412.80
(202.65–622.94) 0.164
165.99
(138.46–198.99)
222.13
(141.40–302.85) 0.202
GFR, mL/min/1.73m2 27.98 ± 13.48 19.54 ± 11.78 0.104 40.97 ± 13.86 32.95 ± 13.48 0.182
Albumin, g/L 40.18 ± 5.93 37.40 ± 7.07 0.256 43.47 ± 3.24 40.57 ± 2.70 0.049
Uric acid, 𝜇mol/L 475.45 ± 88.20 403.40 ± 79.88 0.035 408.39 ± 71.39 382.38 ± 89.62 0.435
Urea, mmol/L∗ 15.20(12.56–17.85)
19.20
(13.44–24.95) 0.157
10.47
(8.36–13.12)
14.02
(9.30–18.74) 0.229
Cholesterol, mmol/L 5.51 ± 1.20 5.25 ± 1.53 0.596 5.63 ± 0.97 6.49 ± 1.19 0.064
LDL-cholesterol, mmol/L 3.38 ± 0.99 3.46 ± 1.36 0.859 3.41 ± 0.64 4.25 ± 1.02 0.019
HDL-cholesterol, mmol/L 1.22 ± 0.22 1.06 ± 0.18 0.045 1.28 ± 0.39 1.30 ± 0.31 0.904
Triglyceride, mmol/L∗ 1.58(1.25–2.00)
1.73
(1.16–2.58) 0.653
1.78
(1.47–2.17)
2.05
(1.75–2.40) 0.232
Fibrinogen∗, g/L 4.51(4.02–5.06)
5.38
(4.03–7.21) 0.166
4.58
(3.94–5.31)
4.65
(3.55–6.08) 0.909
hs-CRP∗, mg/L 0.45(0.28–0.73)
5.96
(1.02–34.91) 0.010
1.53
(0.74–3.17)
1.79
(0.87–3.71) 0.772
IL-6∗, pg/mL 1.93(1.44–2.60)
4.58
(3.21–6.53) <0.001
4.29
(2.96–6.19)
3.97
(2.64–5.97) 0.802
SAA∗, mg/L 2.18(1.92–2.47)
3.78
(2.06–6.97) 0.006
9.86
(5.96–16.37)
8.88
(3.71–21.28) 0.809
NT-proBNP∗, ng/L 232.27(79.43–679.20)
645.65
(245.47–1258.1) 0.104
199.99
(91.83–435.51)
348.34
(183.65–660.69) 0.353
SDMA∗, 𝜇mol/L 1.34(1.19–1.51)
1.97
(1.69–2.28) <0.001
1.25
(1.10–1.42)
1.30
(0.90–1.89) 0.759
O2
∙−, 𝜇mol/min L 49.77(34.83–71.29)
28.84
(9.86–84.14) 0.154
46.56
(33.73–64.27)
44.67
(35.73–55.85) 0.860
Continuous variables are presented as mean ± standard deviation and compared by Student’s 𝑡-test, whereas categorical variables are presented as relative
frequencies and compared by Chi-square test.
∗Values for CKD duration, creatinine, urea, TG, fibrinogen, hs-CRP, IL-6, SAA, NT-proBNP, SDMA, and O2
∙− are presented as geometrical mean and 95%
confidence intervals (CIs). Logarithmic transformation of the values was performed before the analysis.
for the prediction of impaired FMD. Unadjusted analysis
showed that high hs-CRP and SDMA were associated with
impaired FMD (Table 2) in CKD and RT patients. SDMA
and hs-CRP levels were associated with impaired FMD in
multivariate analysis (adjustment for GFR), indicating that
high values of both parameters, independently of GFR, could
predict impaired FMD (Table 2).
The ability of inflammation, SDMA, and O
2
∙− to detect
impaired FMD was investigated by ROC curve analysis
(Table 3). The ROC results indicated that hs-CRP (AUC =
0.754, 𝑃 < 0.001), IL-6 (AUC = 0.699, 𝑃 = 0.002), and
SDMA (AUC = 0.689, 𝑃 = 0.007) had the highest ability to
detect impaired FMD (Table 3). From examined parameters,
the highest sensitivity for impaired FMD was 84.8% for
SDMA, and the highest specificity was for hs-CRP (75.8%).
A combination of SDMA or O
2
∙− with hs-CRP did not
increase hs-CRP’s ability to discriminate impaired FMD from
nonimpaired FMD.Nevertheless, the combination of hs-CRP
with SDMA and O
2
∙− slightly increased the discriminative
ability of hs-CRP alone (AUC = 0.756, 𝑃 = 0.004). We also
investigated the potential benefit of adding SDMA or/and
O
2
∙− to IL-6 in order to better discriminate subjects with
impaired FMD from subjects with nonimpaired FMD. The
addition of SDMA increased the AUC for IL-6 (AUC =
0.732, 𝑃 = 0.001). On the other hand, the AUC for the
combination of SDMA, O
2
∙−, and IL-6 was lower (AUC =
0.724, 𝑃 = 0.003). SDMA in combination with inflammatory
parameters and/or O
2
∙− had better screening performance
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Table 2: OR for impaired FMD in CKD and RT patients.
Unadjusted OR OR adjusted for GFR
SDMA 5.25 (1.894–14.550)
𝑃 = 0.001
3.342 (1.030–10.847)
𝑃 = 0.045
hs-CRP 4.24 (1.677–10.746)
𝑃 = 0.002
3.738 (1.450–9.638)
𝑃 = 0.006
IL-6 2.10 (0.841–5.262)
𝑃 = 0.112
/
SAA 2.381 (1.000–5.665)
𝑃 = 0.051
/
O2
∙− 0.844 (0.313–2.280)
𝑃 = 0.739
/
OR: odds ratio; CI: confidence interval. SDMA, hs-CRP, IL-6, SAA, andO2
∙−:
categorical variables.
than SDMA alone.This improvement in AUCs for all models
was not higher than theAUC for hs-CRP alone. After internal
validation of the models, the mean hs-CRP AUC of the
1000 bootstrap samples was 0.735 (95%CI: 0.628–0.840).The
application of the hs-CRP, SDMA, and O
2
∙− model to the
same bootstrap samples yielded a mean AUC of 0.741 (95%
CI: 0.616–0.859) (Table 3). Both the mean AUCs showed
useful discriminative ability for impaired FMD.
Assuming that no patients with impaired FMD should
be missed when screening (i.e., sensitivity of 100%), the hs-
CRP, SDMA, and O
2
∙− model achieved a specificity of 29.2%
compared to 24.2% using hs-CRP alone. However, for the low
predicted probability (0.10 or less) for impaired FMD, false
negative value was 0% for both models.
4. Discussion
Our findings suggest that impaired endothelial function is
associated with increased inflammatory activity in CKD
patients, as assessed by the measurement of several biochem-
ical markers such as IL-6, hs-CRP and SAA. The current
results were expected as IL-6 promotes synthesis of CRP, and
SAA in the liver while CRP decreases NOS expression [11, 12].
Only a few reports described associations between IL-
6, CRP, and/or SAA and endothelial dysfunction in RT
recipients. Cueto-Manzano et al. [13] demonstrated that after
renal transplantation, CRP decreases despite a rise in IL-6.
Endothelial function is improved after renal transplantation,
but not in the early posttransplant period [14]. In the long
term, renal transplantation improves endothelial function,
but not inflammation. This finding suggests that some other
factors influence posttransplant inflammatory activity of
individual markers. The results of our study agree with these
previous reports because we did not find any differences
in inflammatory markers between the FMD groups in RT
recipients.
An increase in LDL-cholesterol is common after renal
transplantation, due to immunosuppressive therapy and
posttransplant renal function. LDL-cholesterol was signifi-
cantly different whenRTpatients with andwithout FMDdys-
function, after adjustment for GFR, were compared [15, 16].
This finding indicates that LDL- cholesterol alters endothelial
function which is an early step in the development of
cardiovascular disease.
A number of studies have highlighted a connection
betweenADMAand endothelial dysfunction in nonrenal and
renal patients [2, 17–19]. Among patients with chronic renal
failure, markers of oxidative excess correlate with endothelial
dysfunction. Reactive oxygen species (ROS) decrease NO
bioavailability and upregulate adhesion molecules (VCAM-
1, ICAM-1, and E-selectin) and chemotactic molecules
(macrophage chemoattractant peptide-1) [20]. The expres-
sion of these molecules plays an initial role in an inflam-
matory process and ruinous step of forming foaming cells
of atherosclerotic plaque. Probably, there are other factors
to contribute to these mechanisms. For instance, in dia-
betic patients ROS also enhance expression of interleukin-
6 leading to a vicious circle of diabetic nephropathy [21].
Also, reduced NO downregulates its function in preventing
adhesion and aggregation of other cells such as platelets
through cyclic guanosine monophosphate, so that the rolling
phenomenon of platelets over vonWillebrand factor predom-
inates and the initial signal for thrombosis is ready. All of the
factors mentioned above could discriminate consequences,
but they cannot start the atherothrombogenesis. Instead of
using markers of fire, could we use markers of the first smoke
(e.g., ADMA SDMA), primarily in CKD and RT patients?
As the relationship between SDMA and endothelial
function in CKD patients and RT recipients remains unclear
we assessed whether high SDMA could predict impaired
FMD. According to our results, the relationship between
SDMA and endothelial dysfunction after adjustment for GFR
was statistically significant. ADMA is metabolised mainly by
dimethylarginine dimethylaminohydrolase (DDAH). Renal
excretion is of less importance. In contrast, excretion via
the kidney is the main route for SDMA [22]. Fliser et
al. [23] showed that the correlation coefficient for SDMA
and GFR was almost identical to that of creatinine and
GFR. Such findings suggest that urinary excretion is the
main elimination pathway for SDMA in humans. As SDMA
accumulates eight times more than ADMA in patients with
end stage renal disease, it is reasonable to assume that renal
dysfunction has a major influence on SDMA [24]. Even in
this case, the high value of SDMA independently of GFR
increased the probability for the development of endothelial
dysfunction. In addition, SDMA is not a direct inhibitor of
NOS unlike ADMA. Nevertheless, the influence of SDMA
on the endothelium may be as important as that of ADMA.
The fact that we find significant association between SDMA
and impaired endothelial dysfunction means that SDMA
could be a biomarker with clinical significance. A recent
study by Schepers et al. [25] suggested that SDMA, but
not ADMA, stimulated monocytic ROS production in CKD
thereby exhibiting proinflammatory effects. Interestingly in
another study [26], the acute inflammation was characterised
by a decrease in ADMA, but not SDMA. A key question
is whether SDMA and ADMA have different metabolic
pathways and play different pathophysiological roles. Further
studies are required to fully evaluate the influence of SDMA
on the cardiovascular system in renal patients.
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Table 3: The results of ROC analysis for discriminating impaired from non-impaired FMD.
AUC (95% CI) Std. error Sensitivity % Specificity % AUC (95% CI)b P
SDMA 0.689 (0.549–0.829) 0.071 81.8 58.3 0.686 (0.540–0.820) 0.007
hs-CRP 0.754 (0.602–0.905) 0.054 73.3 75.8 0.735 (0.628–0.840) <0.001
IL-6 0.699 (0.597–0.802) 0.052 72.3 52.6 0.690 (0.579–0.789) 0.002
SAA 0.605 (0.486–0.725) 0.061 76.7 51.4 0.093
O2
∙− 0.593 (0.467–0.719) 0.064 69.2 34.5 0.174
Model: hs-CRP and SDMA 0.730 (0.582–0.878) 0.076 0.728 (0.592–0.855) 0.005
Model: hs-CRP and O2
∙− 0.671 (0.531–0.812) 0.072 0.639 (0.517–0.771) 0.025
Model: hs-CRP, SDMA, and O2
∙− 0.756 (0.623–0.888) 0.068 0.741 (0.616–0.859) 0.004
Model: IL-6 and SDMA 0.732 (0.614–0.851) 0.061 0.704 (0.593–0.813) 0.001
Model: IL-6 and O2
∙− 0.628 (0.507–0.749) 0.062 0.070
Model: IL-6, SDMA, and O2
∙− 0.724 (0.570–0.878) 0.079 0.715 (0.566–0.846) 0.003
Model: SDMA and O2
∙− 0.737 (0.598–0.876) 0.071 0.655 (0.533–0.778) 0.002
Data in parentheses are 95% confidence intervals (95% CIs). Sensitivity and specificity were calculated for optimal cutoff value. bThe AUC and 95% confidence
intervals of the 1000 bootstrap samples.
Several studies have shown that CRP is a risk factor
for cardiovascular events and causes mortality in different
cohorts of renal patients [27–30]. In addition, a growing
number of studies found a link between inflammation and
endothelial function in CKD patients [31–33]. Endothelium
synthesized several biochemical markers. Each of them has
an important role in the development of inflammation
(ICAM-1, VCAM-1, von Willebrand factor, and E-selectin)
[34]. Therefore, testing the association between indicators
of renal function, inflammation and endothelial dysfunction
may provide more evidence that different pathophysiological
mechanisms lead to cardiovascular and renal disease. In our
study, the individual marker which showed the strongest
association with FMD was hs-CRP. Our finding agrees with
that of Recio-Mayoral et al. [35], as hs-CRP showed a
significant negative correlation with the percentage of FMD
in predialysis, dialysis, and kidney transplant recipients.
Furthermore, our data provide novel evidence that hs-CRP
may predict impaired endothelial function measured by the
diameter of the brachial artery in CKD patients.
Our study evaluated the diagnostic accuracy of hs-
CRP, IL-6, SAA, SDMA, and O
2
∙− to detect endothelial
dysfunction in CKD patients. In the whole patient group,
ROC curves of single markers indicated that only hs-CRP,
IL-6 and SDMA had the ability to detect impaired FMD.
In addition, the AUC value was higher for hs-CRP than
for IL-6, and SDMA. According to our knowledge there
is no data about SDMA diagnostic ability, sensitivity and
specificity for impaired FMD detection in CKD and RT
patients. Schepers et al. [25] examined the discriminative
power of SDMA in CKD patients for inflammation. AUC
was 0.69 and sensitivity and specificity were 71% and 70%,
respectively. In our study SDMA sensitivity for impaired
FMD was 81.8%, and it was the best sensitivity compared to
other markers. The multimarker strategy that assumes the
choice of an adequate set of biomarkers was used to construct
ROC curves. All combinations of markers appeared to have
comparable AUCs, ranging from 0.724 for IL-6/SDMA/O
2
∙−
to 0.756 for hs-CRP/SDMA/O
2
∙−. None of the models had a
significantly better AUC compared with the AUC for hs-CRP
alone (0.754). Swets [36] suggests the following guidelines for
interpretation of AUCs: 0.5–0.7 rather low accuracy; 0.7–0.9
accuracy useful for some purposes;>0.9 rather high accuracy.
However, the basic intent of the models for predicting
impaired FMD is to avoid additional analyses in subjects
without impaired FMD. Therefore, a correct classification
of subjects with low risk for impaired FMD is important
measure of the model performance. According to models in
our study, subjects with 0.10 or less predicted probability for
impaired FMD had 0% false negative values. This means that
no subject with impaired FMD will be classified as a subject
without impaired FMD if the values of the parameters in
the model are higher than the calculated cutoffs. Similarly
for screening tests, the sensitivity is of prime importance
and so is the negative predictive value. The level of false-
positive values must be kept low enough in order to preserve
both specificity and positive predictive value at acceptable
levels [37]. In our study, in case of 100% sensitivity, false-
positive values (1-specificity) were 70.8% and 75.8% for hs-
CRP/SDMA/O
2
∙− model and hs-CRP alone, respectively. As
pointed out by Dodd and Pepe [38], “large monetary costs
result from high false-positive rates.”
Clearly SAA and O
2
∙− had poor ability to detect FMD in
CKD.This poor performance ofO
2
∙−may be explained by the
fact that different oxidative pathways exist in uremia. Which
of these pathways have the greatest influence is still unknown.
It seems that chlorinated oxidative stress is more important
than nitrosative stress [39]. Therefore, other biochemical
parameters of oxidative stress should be examined.
Unexpectedly, our study showed that the combined use of
chosen biomarkers provides very little, if any, contribution to
screening power for endothelial dysfunction comparing with
that provided by the sole hs-CRP. It is obvious that different
pathophysiological processes provide overlapping informa-
tion regarding screening potential for endothelial dysfunc-
tion. Future investigations should address other biomarkers
for each step that leads to endothelial dysfunction, especially
biomarkers of endothelial cell activation (vWF, ICAM-1,
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VCAM-1, and E-selectin). Practical application of SDMA and
other biomarkers demands both basic research and clinical
trials. The use of these biomarkers can be recommended
in clinical studies for the purpose of better understanding
the endothelial dysfunction or to predict it in different
population groups.
5. Limitations
The relatively small sample size could influence statistical
power (especially when categorical variables were used) for
multivariate analysis and there is a possibility of missed asso-
ciations which could otherwise be detected in a larger study
group. In spite of the small number of patients, the study
offers an objective comparison of endothelial dysfunction
and different biomarkers in CKD patients and RT recipients.
6. Conclusion
The data presented here suggest that a strong predictable
association exists between hs-CRP, SDMA, and endothelial
dysfunction inCKDpatients andRT recipients. Furthermore,
the individual marker which showed the strongest discrim-
inative ability for endothelial dysfunction is hs-CRP when
compared with IL-6, SDMA, SAA, and O
2
∙−. We did not find
any relationship between endothelial dysfunction and O
2
∙−.
Further studies incorporating a larger number of patients to
evaluate influence of the othermarkers of oxidative stress and
endothelial cell activation on the cardiovascular system in
CKD patients and RT recipients are desirable. Also, further
studies should consider the cost effectiveness of a screening
test with a high number of false positive values.
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